Tarsus Bets Strong XDEMVY Launch on High-Risk Stargardt Disease Acquisition

Tarsus Reports Strong Q2 XDEMVY Sales, Acquires Alkeus

Tarsus Pharmaceuticals reported strong second-quarter 2026 financial results, with XDEMVY net product sales reaching $173.9 million, marking over 69% year-over-year growth. The company also raised its full-year 2026 XDEMVY sales guidance to $685-705 million. A significant strategic move includes the pending acquisition of Alkeus Pharmaceuticals, which will add ALK-001, a Phase 3 investigational oral therapy for Stargardt disease, to Tarsus's retina pipeline. This expansion was supported by a $125 million private placement financing. Tarsus also provided updates on its clinical pipeline, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both with topline Phase 2 data expected in the first half of 2027. The company reported a net loss of $18.6 million for the quarter and held $449.7 million in cash, cash equivalents, and marketable securities.

• Exceptional XDEMVY Commercial Performance: Tarsus Pharmaceuticals achieved record second-quarter 2026 net product sales of $173.9 million for XDEMVY, its FDA-approved treatment for Demodex blepharitis, representing a substantial increase of over 69% year-over-year. This strong performance led the company to increase its full-year 2026 XDEMVY net product sales guidance to an impressive range of $685-705 million, underscoring robust market demand and effective commercial strategies, including successful direct-to-consumer initiatives.
• Strategic Expansion into Retina with Alkeus Acquisition: Tarsus announced a pivotal agreement to acquire Alkeus Pharmaceuticals, significantly expanding its presence in the retina specialty. This acquisition introduces ALK-001 (gildeuretinol acetate), a differentiated Phase 3 investigational oral therapy targeting the underlying biology of Stargardt disease, an inherited retinal condition affecting over 36,000 patients in the U.S. The deal, supported by a $125 million private placement financing, positions Tarsus to become a leading eye care company with a compelling late-stage pipeline.
• Advancing a Diverse Clinical Pipeline: Beyond XDEMVY, Tarsus provided updates on its promising clinical pipeline. The Phase 2 KORE trial for TP-04, an ophthalmic gel for ocular rosacea, and the Phase 2 Calliope trial for TP-05, an oral prophylactic for Lyme disease prevention, are both progressing well, with topline data anticipated in the first half of 2027. Additionally, the company plans to initiate the Phase 3 COMFORT trial for IRX-101, an ocular antiseptic, in the first half of 2027, with results expected in 2028, further diversifying its therapeutic offerings.

Beyond Demodex Blepharitis: Lotilaner's Expanding Therapeutic Reach

Beyond its established use in Demodex blepharitis, lotilaner has been extensively developed and studied as an oral ectoparasiticide (isoxazoline class) for veterinary applications, particularly flea and tick control in dogs and cats. Multiple laboratory, field, safety, and pharmacokinetic studies underpin this expanded therapeutic profile, spanning trials in the United States, Germany, Hungary, Portugal, France, and Spain.

• Flea and tick infestations in dogs and cats: Efficacy was evaluated against multiple tick species (Dermacentor variabilis, Rhipicephalus sanguineus, Amblyomma americanum, Ixodes scapularis, and the Australian paralysis tick Ixodes holocyclus) as well as flea infestations, using randomized, controlled laboratory designs (dogs ranked/blocked by pre-treatment counts, ≥8 dogs/group) and field studies at multiple veterinary clinics. Efficacy against existing tick infestations was consistently 100%, with post-treatment efficacy maintained at ≥98% for at least 4 weeks.

• Field studies for flea control (dogs): Conducted at 10 US veterinary clinics (lotilaner 20 mg/kg vs. afoxolaner 2.5 mg/kg, 2:1 randomization, dosed Days 0/30/60) and 17 clinics across Germany, Hungary, and Portugal (lotilaner vs. topical fipronil, 2:1 randomization, dosed Days 0/28/56). Lotilaner achieved 99.3–100% flea count reductions, was statistically superior to fipronil, and produced parallel improvements in flea allergy dermatitis (FAD) signs (hair loss, pruritus, erythema, scaling/crusting).

• Field studies for tick control (cats): A 20-clinic study across Germany, Hungary, and Portugal randomized households 2:1 to lotilaner or fipronil, with tick counts performed longitudinally (Days 0–84) in primary cats (≥3 live attached ticks at baseline).

• Safety studies (dogs and cats): Randomized, blinded, parallel-group designs in 8-week-old Beagle puppies and kittens assessed monthly oral dosing over 8 months at 1×, 3×, and 5× the upper recommended dose. Comprehensive monitoring (clinical, ophthalmologic, ECG, hematology, histopathology) confirmed lotilaner was well tolerated, with no clinically relevant treatment-related findings even at 5× overdose.

• Pharmacokinetic studies (dogs and cats): Studies in adult Beagles (n=26) and cats (n=26) compared oral (20 mg/kg dogs; 6 mg/kg cats) versus intravenous (3 mg/kg) administration, using validated LC-MS/MS assays and non-compartmental analysis. Key findings included rapid absorption (Tmax ~2 hours), oral bioavailability >80% under fed conditions, low clearance, large volume of distribution, and a terminal half-life of ~30.7 days in dogs—supporting sustained once-monthly dosing efficacy.

• Sarcoptic mange (dogs): A related isoxazoline, sarolaner, was evaluated for Sarcoptes scabiei in placebo-controlled laboratory and multi-center field studies, contextualizing the broader isoxazoline class efficacy against mite-related dermatoses.

Shaping Eye Care: Tarsus's Strategic Expansion into Retina

The treatment landscape for Demodex blepharitis has been fundamentally transformed by the introduction of the first FDA-approved therapy, lotilaner ophthalmic solution 0.25%. Clinical trial data has established lotilaner as a highly effective and well-tolerated ectoparasiticide. Meta-analyses show a significantly higher likelihood of mite eradication (RR 3.55) and clinically meaningful reduction in collarette scores (RR 3.15) compared to control groups. With up to 93% of patients in clinical studies achieving a significant collarette reduction and a favorable safety profile—with 92% of trial participants finding the drop neutral to very comfortable—lotilaner is positioned to become the new standard of care, addressing the limitations of previous off-label options.

Concurrently, research has advanced our understanding of other acaricidal agents. Topical ivermectin 1% has demonstrated significant efficacy, with studies showing mean reductions of 70.01 mites/cm², sustained effects for up to 12 weeks post-treatment, and only mild, localized adverse events. While the efficacy of traditional treatments like tea tree oil (TTO) has been consistently confirmed, newer formulations aim to mitigate its known ocular irritation. Emerging candidates include selenium sulfide-containing ophthalmic ointment (AZR-MD-001), which showed complete but temporary resolution of blepharitis in a case study, and non-pharmacologic approaches like Intense Pulsed Light (IPL) therapy, which has proven effective for mite control. In contrast, the role of topical corticosteroids and cyclosporine remains less certain, with evidence suggesting very low to uncertain effects on composite symptom scores for Demodex blepharitis.

Addressing Unmet Needs: Tarsus's Vision for a Diverse Eye Care Pipeline

Demodex blepharitis represents a chronic, underdiagnosed condition with substantial diagnostic ambiguity, limited historical treatment options, and specific patient populations bearing a disproportionate disease burden. Despite the 2023 approval of lotilaner ophthalmic solution 0.25% (Xdemvy) as the first FDA-sanctioned therapy, significant gaps persist across diagnosis, treatment durability, and access — underscoring the rationale for continued pipeline investment in this space.

• Diagnostic uncertainty: No standardized diagnostic criteria exist for Demodex-associated blepharitis, complicated by an unclear pathogenesis, nonspecific clinical signs, and the fact that mites can be detected in asymptomatic individuals — driving calls for systematic scoring systems (e.g., a score ≥4 correlating with 94% Demodex positivity) to enable accurate diagnosis, particularly where advanced facilities are unavailable.

• Historical treatment inadequacy: Prior to lotilaner's approval, management relied on empirical, non-standardized approaches — including lid hygiene, tea tree oil, metronidazole, and ivermectin — which showed limited and inconsistent efficacy (e.g., mean mite counts remained elevated at 9.4–22.0 after two months across regimens) and, in some cases, notable side effects or resistance; 94 of 96 patients required treatment beyond basic lid hygiene alone.

• Chronic, treatment-refractory disease burden: Patients experience prolonged disease courses (averaging 4.3 years) with delayed diagnosis (~1.2 years from symptom onset), frequent healthcare utilization (mean 3.9 visits/year), and persistent or recurrent symptoms — redness, dryness, and itchiness — even after diagnosis and management, highlighting an unmet need for therapies addressing root-cause mite eradication rather than transient symptom control.

• High-risk and underserved subpopulations: Distinct groups face elevated risk or complexity, including elderly patients (≥60 years, at greater risk of infestation and more severe meibomian gland dysfunction), immunocompromised patients (risk of massive symptomatic infestation), patients with autoimmune/rheumatologic conditions such as secondary Sjögren syndrome, and patients on proteasome inhibitors (e.g., bortezomib) who develop treatment-related chalazia/blepharitis — each requiring tailored therapeutic strategies.

• Underrecognition in clinical practice: Demodex-related blepharitis remains an underreported cause of disease in urban settings, and drug-induced ocular surface manifestations (e.g., blepharitis associated with dupilumab in atopic dermatitis patients) are frequently underdiagnosed, with pharmacists often serving as the first point of contact due to nonspecific presentation.

• Quality-of-life and complication risk: Beyond ocular discomfort, patients report decreased self-esteem and confidence, and untreated or poorly managed disease can progress to dry eye syndrome, corneal scarring, and recurrent chalazia/styes — reinforcing the need for durable, well-tolerated therapeutic options.

• Emerging therapeutic momentum with residual gaps: While lotilaner has demonstrated strong compliance (~98.7%) and comfort ratings (90.7–92.0% neutral-to-very comfortable), and topical ivermectin 1% has shown low discontinuation rates in large cohorts (2,157 patients), the field still lacks standardized treatment algorithms, long-term outcome data, and consensus on optimal management for treatment-resistant or complex cases.